Patent US5283067A successfully refreshed from Google Patents.
US5283067A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Parenteral suspensions
Assignee: Novartis Corp
•
Filing: 1993-02-11
•
Granted: 1994-02-01
•
Expires: 2013-02-11
Abstract
Abstract The invention relates to a dry formulation, in particular a dry formulation obtainable by lyophilisation, which is suitable for the preparation of a stable, aqueous suspension for the parenteral administration of a diclofenac salt. The dry formulation contains a pharmaceutically acceptable and micronised salt of diclofenac and optional pharmaceutically acceptable adjuvants.
Inventors
- 👤 Leo Geller
- 👤 Peter Glanzmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:09
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K9/00; A61K9/14
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
53 words
A suspension administrable to humans by intramuscular injection consisting essentially of: (a) 1-3 ml of sterile water; and (b) 25-150 mg of a sterile, lyophilized formulation of micronized diclofenac sodium and at least one pharmaceutically acceptable adjuvant for establishing isotonic conditions selected from the group consisting of sodium chloride, sorbitol, mannitol and glucose.
Claim 2
Dependent Claim
53 words
A suspension administrable to humans by intramuscular injection consisting essentially of: (a) 1-3 ml of sterile water; and (b) 25-150 mg of a sterile, lyophilized formulation of micronized diclofenac sodium and at least one pharmaceutically acceptable adjuvant for establishing isotonic conditions selected from the group consisting of sodium chloride, sorbitol, mannitol and glucose.
Claim 3
Dependent Claim
70 words
A process for the preparation of a suspension administrable to humans by intramuscular injection which process steps are consisting essentially of: (a) preparing a sterile, lyophilized formulation of diclofenac sodium in micronized crystal form and at least one pharmaceutically acceptable adjuvant for establishing isotonic conditions selected from the group consisting of sodium chloride, sorbitol, mannitol and glucose; (b) adding 1-3 ml of sterile water; and (c) suspending the lyophilized formulation.
Claim 4
Dependent Claim
70 words
A process for the preparation of a suspension administrable to humans by intramuscular injection which process steps are consisting essentially of: (a) preparing a sterile, lyophilized formulation of diclofenac sodium in micronized crystal form and at least one pharmaceutically acceptable adjuvant for establishing isotonic conditions selected from the group consisting of sodium chloride, sorbitol, mannitol and glucose; (b) adding 1-3 ml of sterile water; and (c) suspending the lyophilized formulation.
References Cited (Backward Citations)
GB1373913A
Cited
US3973024A
Cited
US4332795A
Cited
US4378354A
Cited
US4309421A
Cited
US4614741A
Cited
US4593044A
Cited
US4593044B1
Cited
US4880634A
Cited
GB2166651A
Cited
US4711906A
Cited
EP0236855A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-01-31 | 1997-08-02 | 1998-02-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-01-31 | 2001-08-02 | 2002-02-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-01-31 | 2005-08-02 | 2006-02-01 | $7700.00 | Window Closed / Lapsed |